FDA OK's Pfizer/Ligand hot flash, osteoporosis drug Duavee
This article was originally published in Scrip
The fact that it was operating with only about half its staff during a government shutdown did not keep the US FDA from approving new medicines this week – granting Pfizer the OK to market its hot flash and osteoporosis drug Duavee (conjugated estrogens/bazedoxifene), the pharma giant revealed on 3 October.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.